Skip to content

Author

Bing Xu

We have 2 of 38 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Real-world treatment patterns and outcomes of brentuximab vedotin–based therapy in CD30-positive lymphomas in China: the prospective BRAVE study

To the Editor Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, has transformed the treatment landscape through ECHELON trials, including ECHELON-1 in previously untreated advanced-stage classical Hodgkin lymphoma (cHL) [1], ECHELON-2 in peripheral T-cell lymphoma (PTCL) [2], and ECHELON-3 in relapsed...

Ming-Ci Cai, O. Bai, Hui-Lai Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.